Try our Advanced Search for more refined results
Life Sciences - October, 2018
325 articles
- Allergan, Generic Cos. Battle Over Restasis Launch Plans
- Groundskeeper Accepts Slashed $78M Roundup Award
- Myriad Genetics Tries To Ditch Billing Fraud Stock Drop Suit
- Consumer Sent To Drawing Board On Tainted Drug Claims
- HHS Reverses Course, Will Start 340B Fines Soon
- Weil Gotshal Lawyers' Tough Tactics Sealed J&J Talc Win
- Pa. Appeals Court Upholds $2.5M Philly Risperdal Verdict
- Deals Rumor Mill: Athenahealth, CVC, Thermo Fisher
- 3 Health Care IPOs Net $390M Total To Close Choppy October
- Pharma Co. Egalet Hits Ch. 11 With $129M Debt
- Justice Alito Unrecuses Self From Merck's Fosamax Appeal
- US Narrows Bid For Israeli Court Docs In $163.5M Tax Row
- Judge Pauses Invalidation Of Patent For Janssen's Zytiga
- Boston Says Opioid Suit Is Purely A State Law Matter
- Israeli PE Firm Shavit Nabs $100M For Latest Fund
- Juul Labs Gets Some Claims Tossed In E-Cig Labeling Suit
- Why Current Laws Won't Protect Property Rights For DNA
- Tips For Drafting M&A Agreements After Akorn
- Assessing Innovations For Medical Device Development
- Genentech Sues Over Stolen Secrets; 4 Ex-Workers Indicted
- FCA Decision Tracker: Continued Interpretations Of Escobar
- DC Circ. Backs FDA Denial Of Rx-Only MiraLAX Generics
- Ex-Valeant Exec, Pharmacy CEO Get Year For Kickback Fraud
- Celgene Corp. Drug Buyers Denied Cert. In Antitrust Suit
- Akorn Says Chancery Rewrote Law In Letting $4.3B Deal Die
- Ill. AG Sues Sterigenics Alleging Pollution Problems
- Conflicting Verdict Sunk Lotion Trademark Row, 3rd Circ. Told
- Waxman Opposes Hatch Plan To Keep Generics Out Of PTAB
- Drs. Group Urges FTC Antitrust Scrutiny Of Insulin Pricing
- Amarin Says Supplement Cos. Can't Tout Its Omega-3 Trial
- Investor Attys Seek $8.5M In $43M Medtronic Stock-Drop Deal
- Defendants Can't Be Held To Impossible Discovery Standards
- Building The Regulatory Conversation On Cellular Agriculture
- Protecting Law Firm Talent At Both Ends
- Insurer Wants Out Of Covering Pharma Co. In Opioid Suits
- 23andMe's Counterclaims Trimmed In Insurance Dispute
- Perrigo Hit With Investors' Suit Over Thwarted Mylan Deal
- Judge Lets FTC Slip Allergan's Suit, But Rips Venue Conduct
- White & Case Leads EQT In $654M Karo Pharma Bid
- NJ Judge Invalidates Patent For Janssen Cancer Drug Zytiga
- Pharma Co. Gets Pneumonia Drug Stock-Drop Suit Tossed
- Supreme Court Won't Look At HIV Drug Patent Challenge
- Doc Must Get Share Of $3B GSK Settlement, NJ Court Says
- Endo Shareholders Fight Bid To Nix Generic Price-Fixing Suit
- Takeda Offers To Sell Shire Drug To Get EU's OK For Takeover
- Wendy Olson Talks Twin Falls, Tribes, Private Practice
- How SUPPORT Will Affect Pharma Interactions With DEA
- Solicitor General Asked To Weigh In On Roche Patent Appeal
- J&J Can't Arbitrate Distributor's Claims In Remicade Row
- 12 Firms To Guide Six IPOs Raising $468M Amid Dicey Market
- Mass. Priest Wants Out Of SEC's $1.3M Short-Selling Suit
- Teva's Off-Label Fentanyl Promotion Fueled Crisis, Ky. Says
- Only Loestrin Market Matters In Antitrust Row, Retailers Say
- Allergan, Tribe Want IPRs Blocked As They Turn To High Court
- Investor Seeks Records From Harbor Pharma Research Co.
- Pa. Man To Address Time Limit In Covidien Hernia Mesh Suit
- Abbott, AbbVie Pay $25M Over Off-Label Promos, Kickbacks
- Former Ice Miller Partner Rejoins Firm's Business Practice
- $400M Arbitral Award Against Czechs Isn't Binding: DC Circ.
- 11th Circ. Orders New Trial Over Incontinence IP Fraud
- Judging A Book: Brown Reviews 'Dangerous Leaders'
- Patent Dance Developments: A Tale Of 2 Antibodies
- Ropes & Gray Adds Ex-FDA Enforcement Pro In DC
- 5 Takeaways As Trump Eyes Cut To Medicare Drug Payments
- Valeant Poised To Pursue Label Suits Over IBS Drug Copycats
- USPTO Can't Pause Patent Fee Row To Mull High Court Bid
- L'Oréal Ex-VP Fired After Pointing Out Toxic Workplace: Suit
- Exxon, Chevron, Others Keep Gas Additive Suit In Fed. Court
- DOJ Unveils Appalachian Opioid Strike Force, $35M For Kids
- Biopharma Dodges Fund's Suit Alleging It Reneged On Shares
- Exforge Generic Deal Is Clear Antitrust Violation, Court Told
- Full Fed. Circ. Urged To Rehear 'Blocking Patents' Ruling
- A First Look At The Sweeping New Opioid Law
- Breaking The Rules: 3 Ways To 'Lead' A Direct Examination
- Trump Signs Vast Opioid Legislation Into Law
- Bressler Amery Launches Cannabis Practice In Fla., NJ
- Women's Expert Witnesses Axed In Bayer Mirena MDL
- Deals Rumor Mill: CommScope, Endeavor, Innovent
- Justices Told $200M Merck IP Award Should Be Reinstated
- Teva Asks FTC To Tweak Watson-Actavis Merger Fix
- Shkreli, Ex-Firm Hit With Antitrust Suit Over Kidney Drug
- NJ Law Applies In Bard Pelvic Mesh Multicounty Litigation
- J&J Unit Snags Win Over Glucose Test Strips Patent
- UK Probes Thermo Fisher's Buy Of Electron Microscope Co.
- Biogen Prevails In Fed. Circ. MS Drug Dispute With Forward
- EHealthline's Ex-JV Partners Beat Trade Secrets Suit
- A Closer Look At CMS' Drug Price Disclosure Proposal
- 1st Circ. Weighs In On Uninjured Class Members Issue
- From Medicine To Sexbots, AI Raises Liability Questions
- Gibson Dunn Steers $625M Sale Of Kraft Heinz India Brands
- Takeda Tries Again To Shake Actos Antitrust Claims
- FDA Warning Wire: Global Crackdown On Online Drug Sales
- CORRECTED: ICE's IP Unit Seizes Illegal, Unsafe Decorative Contact Lenses
- FDA Focus: What Loeb & Loeb's Practice Chair Is Watching
- Recycled Arguments Doom Piglet Vaccine Patent Challenge
- Eye Products Supplier Must Face DOJ's Kickbacks Suit
- AstraZeneca Expands Cancer Work With €62.6M Innate Stake
- Insurers Are Well-Positioned To Address Opioid Epidemic
- UK Biotech Orchard Primes $200M IPO Led By Goodwin
- Cravath Steers $2B J&J's Japanese Cosmetics Co. Buy
- Landmark Roundup Verdict Survives, But Cut Down By $211M
- Fed. Circ. Rejects Bid For PTAB Tribal Immunity Rehearing
- Medical Co. Inks $5.25M Deal To End FCA Accusations
- Labs Say UnitedHealth Can't Sue On State Fraud Claims
- Desmarais To Expand With New Bay Area Office
- Desmarais Adds Ex-Sidley Pair As Life Science Partners
- DePuy Can't Undermine $8.2M Patent Verdict, Court Told
- NECC Pharmacy Tech Testifies About Hijinks In Drug Lab
- Gov'ts Must Link Patient Data To Prescriptions In Opioid MDL
- Med Device Biz, Chinese Fintech Launch IPOs Totaling $141M
- Allergan Fights For Ropes & Gray Docs In Compounder IP Suit
- Takeaways From Senate Antitrust Enforcement Hearing
- Md. Asks Justices To Revive Generic-Drug Price-Gouging Law
- Fla. Pharmacy Hit With False Claims Suit Over Kickbacks
- Three Firms Guide Launch Of $508M In IPOs
- 8 Firms To Guide IPOs Surpassing $1.6B In Seesaw Market
- FDA Scraps Demands On Clinical Trial Falsity Reports
- Pharma Co. Wants Sex Drug Marketing Case Axed
- Pfizer Escapes Aussie Antitrust Watchdog's Lipitor Case
- Gov't Asks 9th Circ. To Revive New Birth Control Rules
- Cancer-Drug Maker Nabs $80M Financing, Names New CEO
- AbbVie Deal Clears 5th Humira Biosimilar To Launch In 2023
- Fake Patient Names Take Center Stage At 3rd NECC Trial
- J&J Unit Agrees To Risperdal Deal Ahead Of Philly Trial
- Need Litigation Finance? Don't Skip These 5 Steps
- Assessing Employment Rights Of NJ Medical Marijuana Users
- Medical Device Maker Sued Over 'Dangerous' Walking Boot
- Are You Ready For Your Congressional Investigation?
- Allergan Must Produce CEO's Tribal Patent Docs In MDL
- Teva Sues FDA Over New Stance On Generic-Drug Exclusivity
- Ex-J&J Employee Says She Was Fired For Whistleblowing
- Vitamin Distributor Can't Dodge $9M Default: Ill. High Court
- West Va. Jury Awards $1.2M In Pradaxa Blood Thinner Case
- Bristol-Myers, Pfizer's Blood Thinner IP Suit Axed Over Venue
- Eisai Downplayed Drug's 'Homicidal' Side Effects, FDA Says
- Casino Biz Prices $359M IPO, Biotech Firms Fall Short
- Miramar Finalizes Settlement Over Sientra Merger Suit
- McMillan Steers IAnthus, MPX In $683M Cannabis Co. Merger
- Jury Told Of Seized Drugs, Unsafe Workplace At NECC Trial
- LabMD Exec Sees FCA Suit Against Tiversa Trimmed
- Horizon Wants DLA Piper DQ'd In Hemophilia Treatment Row
- Glenmark Moves To Ax Zetia Pay-For-Delay Claims
- A New Framework For 'Blocking Patents' And Obviousness?
- Amgen Makes £50M Investment In Genetic Sequencing Co.
- Cravath, Faegre Steer Novartis' $2.1B Deal For Endocyte
- Aceto Execs Hit With Derivative Suit Over Stock Drop
- FTC On Ropes As Courts Wallop Suits Over Past Conduct
- A High Court Milestone Stirs Hope Of Gender Parity
- Cooley-Led Med Device Co. Prices $108M IPO Amid Volatility
- J&J Wants $20M Pa. Mesh Award Axed Over Alleged Time Bar
- 20 Drugmakers Must Face Generic Price-Fixing MDL
- Bayer Cholesterol Drug FCA Suit Survives Dismissal Bid
- 2 Biotech Cos. Launch IPOs Despite Erratic Market Conditions
- Calif. Tribes Become Latest To Bring Opioid Crisis Suits
- Imerys Fights Jurisdictional Ruling In NJ Asbestos Talc Row
- Lens Makers Look To Nix Price-Fixing Claims From MDL
- Co-Owner Of NY, NJ Pharmacies Charged With Tax Fraud
- Pfizer Can't Derail EpiPen Pay-For-Delay Discovery: 2nd Circ.
- Quick Chancery Appeal Sought For Rocky $4.8B Akorn Merger
- Policy Groups Back Teva In On-Sale Bar Case At High Court
- Teva, Eagle Fight To Block Generic Versions Of Chemo Drug
- Opioid MDL Gov'ts Must ID Prescriptions Or Limit Evidence
- Firms Win $3M In Fees In Hartig Product-Hopping Suit
- Trump's Rulemaking Agenda Aims To Cut $18B In Costs
- Pa. Justices Snub Preemption Fight Over Actiq Labeling
- Justices Asked If Sanctions Can Cover Presuit Actions
- FDA Warning Wire: E-Cig Juice Spiked With ED Drugs
- Cardiac Monitoring Patent Invalid Under Alice, Judge Rules
- Investors Sue Keryx Over $1.3B Merger With Akebia
- A Holistic Approach To Client Retention
- 1st Circ. Overturns Class Cert. In Allergan Price Fight
- Trevena Investors Sue Over Stock Drop Tied To Drug Trials
- Sinovac Investor Can't Halt Share Issue In Board Dispute
- The Path To Becoming A Supreme Court Advocate
- A Chat With Allens Pricing Chief Pier D'Angelo
- Ill. Health Insurance Nonprofits Sue Over Opioid Crisis
- Gender Disparity At The High Court: How Top Law Firms Measure Up
- Express Scripts Not Hurt By Alleged Breach, Pharmacies Say
- Opioid MDL Needs Gov't Docs To Advance, Drugmakers Say
- DOJ Charges Florida Men with $1B Telemedicine Fraud Scam
- Deals Rumor Mill: Innovent, Lime, HNA
- Abbott Says Former Exec Stole Marketing 'Playbook'
- $4.8B Akorn Ruling More Outlier Than Shift At Chancery
- 7th Circ. Revives Sex Harassment Witness' Firing Suit
- Ex-NECC Workers Blame Boss In Fraud Case
- Energy Drink Falsely Touts Nutritional Supplements, Suit Says
- Pharma Inventor's Ex-Wife Sues Him Over Patent Ownership
- 4 Key Takeaways As HHS Demands Drug Prices In TV Ads
- CFIUS Pilot Program: Immediate Investment Implications
- Supreme Court Women: A Vet & 1st-Timer Talk Gender Disparity
- Will The Future Of The Supreme Court Bar Be Female?
- Merck, Glenmark Tear Apart Zetia Pay-For-Delay MDL Claims
- 11 Firms To Lead IPOs Raising $1.8B Amid Market Volatility
- Health Hires: Insys, Ex-US Atty, Katten, Kasowitz, Dechert
- Sandoz Humira Biosimilar Set For 2023 After AbbVie Deal
- PTAB Axes Most Of Boston Scientific Stent Patent As Obvious
- Fed. Circ. Rules Teva's Copaxone Patents Are Invalid
- Liberty Mutual Shirking Painkiller Coverage, Pa. Suit Says
- Biotech Co. Slapped With Stock-Drop Suit Over Patent Failure
- Manning Gross, Kurowski Shultz To Join Forces In January
- The ABA Was Dead Wrong About Model Rule 8.4(g)
- K2M Shareholders Move To Block $1.4B Stryker Merger Vote
- Ranbaxy Abused 'First-To-File' For Heartburn Treatment: Suit
- 2 Fraud-Convicted Pharma Analysts Denied Acquittal Bids
- What Akorn Teaches Us About Delaware MAC Clauses
- Experts Highlight Real Estate's Key Role In Fla. Pot Market
- Impax Reverse Payment About Dodging Competition, FTC Told
- Ex-NECC Owner's Income Fair Game At Meningitis Trial
- Justices Urged To Ax Fed. Circ. Drug Patent Obviousness Test
- Drugmaker Urges Court To OK $3.8M Award In Supply Fight
- Drug Cos. Sold Contaminated Blood Pressure Meds, Suit Says
- Pfizer To Pay $700K In NY Penalties Over Drug Pricing Claims
- The Supreme Court Should Become Boring
- Pepper Hamilton Snags Patent Atty From Perkins Coie
- Sinovac Investors' Stock Injunction Bid Faces Skeptical Judge
- Laser Co. Zapped With Stock-Drop Suit Over Alleged Defects
- Cannabis Co. MedMen Picks Up PharmaCann In $682M Deal
- Back To School: BC's Kent Greenfield Talks Corporate Law
- Blue Cross Insurer, LabCorp Beat STD-Testing Antitrust Suit
- Cooley-Led Allogene Raises $324M After IPO Prices High
- The Rise In ESG Investing — And What Boards Can Do
- J&J Scores Trial Win In NJ Asbestos Talc Case
- Monsanto Nears $250M Slash Of Landmark Roundup Verdict
- Investor Says Teva Pharma Lied About Price-Hike Scheme
- J&J Concealed Talc Cancer Risk, NJ Jury Hears In Closings
- Duane Morris Adds Trade Secrets Buff From Knobbe Martens
- Trump Approves Prohibition On Pharmacy 'Gag Clauses'
- Fired Manager Says Abbott Refused To Accommodate Illness
- Deals Rumor Mill: Sears, WeWork, Bayer
- Real Estate Rumors: Alexandria, Atlantic Pacific, Fidelity
- Investors Want Sinovac Capital Frozen Before Caribbean Trial
- BioChemics Receiver Named To Help SEC Sniff Out $17M
- Teva Tells Justices AIA Hasn't Changed On-Sale Bar Meaning
- Fed. Circ. Upholds $20M Cialis Patent Verdict Against Lilly
- AbbVie Faces 2nd Investor Suit Over Humira Kickbacks
- Kavanaugh Cannot Be Compelled To Recuse Himself
- Gov't Brief In Fosamax Makes Strong Case For Reversal
- Eli Lilly Sues French Ex-Partner Over Patent Inventorship
- Opioid MDL Gov'ts Must Pinpoint Improper Prescriptions
- 'Chemo Brain' Should Expedite 2nd Roundup Trial, Judge Told
- FDA Warning Wire: McKesson Policy Lapses, Tainted Cat Food
- Boston Scientific Merger Trial Fast-Tracked In Chancery
- 450 Tribes Demand A 'Seat At The Table' In Opioid MDL
- Knowledge Management: An Unsung Hero Of Legal Innovation
- Justices Won't Tackle Jurisdiction Question In Lipitor Case
- Scooter Startup, Biotech Firm Launch IPOs Totaling $170M
- Gilead, Indian Generic Co. Drop Truvada Infringement Suit
- Fed. Circ. Upholds Decision Axing Roche TB Test Patent
- Adidas Taps Bayer US Legal Head For New General Counsel
- Doc Guilty Of Insider Trading On Wife's Ariad Drug Info
- SG To Argue At Supreme Court For Limiting On-Sale Bar
- Conn. Jury Hands Boehringer 3rd Straight Pradaxa Trial Win
- Ohio County's Opioid Bellwether Gets OK From Magistrate
- Outside Whistleblowers Key To $625M Amerisource FCA Deal
- 6 Firms To Guide 5 IPOs Exceeding $1B Led By Lithium Co.
- Ariad Insider Trading Case Now In Boston Jury's Hands
- Westminster, CVS Sold Bad Thyroid Tablets, Class Suit Says
- Illumina Investors File Class Action Over $6.6B Stock Drop
- Allergan's Sanctions Bill 'Unreasonable,' Imprimis Says
- B. Braun Settles IV Tylenol IP Row After Losing Venue Fight
- Accutane Ruling Raises Bar For Garden State Labeling Claims
- PTAB Invalidates Patent For Biogen's Cancer Drug Rituxan
- What New Calif. Law Means For Connected Medical Devices
- Jury Clears Bard In Third IVC Bellwether Trial
- Purdue Must Face Trimmed Suit Over Opioid Marketing
- Cancer Test Provider Raises $238M In IPO As Shares Soar
- Insurer Owed Nobilis Defense Of Stock Drop Suits: Judge
- Biopharma Co. Sued After Leukemia Treatment Trial Fails
- IQVIA Can't Nix Counterclaims In Trade Secrets Suit
- 3rd Circ. Won't Rehear Talc Suit That Could Move To Calif.
- Intuitive Investors Get $42.5M Deal With Bargain Attys' Fees
- 1st Circ. Won't Rehear Novartis Gleevec Antitrust Suit
- Akorn Could Alter 'Material Adverse Effect' Law In Delaware
- Athena Asks Fed. Circ. To Revive Nixed Biotech Patent
- Disbarred Atty, Ex-Clients Ink $19M Deal In Fen-Phen Case
- J&J Unit Strikes $3.7B Hepatitis B Gene Therapy Deal
- Bard Says Vein Filter Risks Reasonable As Trial Wraps
- J&J Expert: Mesothelioma In Women Rarely Due To Asbestos
- Senate Sends Sweeping Opioid Legislation To Trump's Desk
- Fla. Judge To Block Medical Marijuana Rules
- FDA Petition-Shaming Plan Gives Ammo To Antitrust Suits
- ActiveCare Ch. 11 Sale OK'd With Liability Concerns Resolved
- 4 Firms Break From Pack In Scorching September For IPOs
- Ill. Wants Sterigenics Plant Closed Amid Cancer Concerns
- Talc From EBay Wrongly Kept Out Of P&G Trial, NJ Court Told
- Calif. Man Says Monsanto Can't Get Redo After $298M Win
- PTAB Upholds 2 Genentech Herceptin Patents, Invalidates 1
- NJ Justices Say Garden State Law Topples Accutane Cases
- Skip The New 'Civility Courses' And Think Like A Lawyer
- EHealthline Appeals OK Of $3.5M Award To 9th Circ.
- SEC Enforcement Co-Head Sees Year-End Stats As Overrated
- J&J Suit Over Talc-Cancer Link Sent Back To Pa. State Court
- Deals Rumor Mill: Marathon Oil, Peabody Energy, Atai
- US, China Still Sizing Each Other Up In WTO Tariff Dispute
- Why Law Firms Should Monitor The Dark Web
- Ex-Abbott Researcher Says 'Erroneous' Law Sank FCA Claims
- Claims Trimmed In Bard Vein Filter Bellwether Home Stretch
- Anti-Monopoly Group Wants 1st Circ. To Rehear Novartis Case
- Pfizer, Hospira Urge Final Nix Of Suit Over Faulty Pumps
- Dentons Poaches Trio Of Perkins Coie Patent Litigators
- 2 Cooley-Led Biotech Startups Launch IPOs Totaling $342M
- Ligand Asks Chancery To Toss Costly Formula Error Suit
- ITC Launches Probe Into ResMed Rival's Sleep Mask Imports
- FDA Focus: What Mintz's Practice Chair Is Watching
- Baker Donelson DQ'd In BCBS Antitrust Row Against Ex-Client
- HHS' Acting GC Under Obama Returns To Zuckerman Spaeder
- Fed. Circ. Nixes PTAB Remand In Settled Eye Drug Case
- Does Rule 45 Protect Nonparties From Undue Burden?
- Consumers Seek Sanctions For Mylan In EpiPen Pricing Suit
- Abbott, Distributor Settle 'Gray Market' Test Strip TM Fight
- No Injury Means No Standing For A Talc Plaintiff
- O'Melveny Adds Ex-Paul Hastings IP Partner
- Commerce Ordered To Take 3rd Look At Duties On Radiators
- Amerisource Inks $625M FCA Deal In 'Sham Pharmacy' Row
- Xtampza Not Infringing 2 OxyContin Patents, Judge Says
- Fed. Circ. Upholds Re-Exam Ax Of Athlete Endurance Patents
- Doctor's Duplicative FCA Suit Against MedImmune Dismissed
- Lion Biotech Strikes $3.3M Deal In Stock-Drop Suit
- Life Science Co. Gets $150M Funding From TPG Sixth Street
- Osmotica, Anaplan, Livent IPOs Worth $722M Led By 3 Firms
- Justices Won't Review Janssen's Liability For Risperdal Death
- Doc Traded On Wife's Cancer Drug Knowledge, Jury Hears
- FDA Will Update Cybersecurity Guidance For Medical Devices
- Forbion's 4th Life Sciences Fund Hits $417M In Final Close
- Chancery Lets Fresenius Ditch $4.3B Akorn Deal